Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Johnson

Showing results (181-190 of 218) with videos related to

Pageof 22
Sort By:
Blood Advances|July 28, 2020
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expressionThomas E C Cummin, Kerry L Cox, Tom D Murray, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2016
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell LymphomaLuca Ceriani, Maurizio Martelli, Maria K Gospodarowicz, et al.
British Journal of Haematology|February 6, 2016
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group studyTim M Illidge, Hayley S McKenzie, Sam Mayes, et al.
Biochemical Pharmacology|July 10, 2008
Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin ASimon J Crabb, Melanie Howell, Helen Rogers, et al.
Journal of Clinical Microbiology|June 2, 2000
Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromesH P Endtz, C W Ang, N van Den Braak, et al.
Scientific Reports|February 4, 2018
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linkingAnna H Turaj, Kerry L Cox, Christine A Penfold, et al.
Leukemia|August 1, 2023
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expressionJack G Fisher, Amber D P Doyle, Lara V Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer GroupR M Rudd, N H Gower, S G Spiro, et al.
Pageof 22

Showing results (181-190 of 218) with videos related to

Sort By:
Pageof 22
Blood Advances|July 28, 2020
BET inhibitors synergize with venetoclax to induce apoptosis in MYC-driven lymphomas with high BCL-2 expressionThomas E C Cummin, Kerry L Cox, Tom D Murray, et al.
Haematologica|November 28, 2015
The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trialSimon Rule, Paul Smith, Peter W M Johnson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244Peter J Hoskin, Lisa Lowry, Alan Horwich, et al.
International Journal of Radiation Oncology, Biology, Physics|November 15, 2016
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell LymphomaLuca Ceriani, Maurizio Martelli, Maria K Gospodarowicz, et al.
British Journal of Haematology|February 6, 2016
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group studyTim M Illidge, Hayley S McKenzie, Sam Mayes, et al.
Biochemical Pharmacology|July 10, 2008
Characterisation of the in vitro activity of the depsipeptide histone deacetylase inhibitor spiruchostatin ASimon J Crabb, Melanie Howell, Helen Rogers, et al.
Journal of Clinical Microbiology|June 2, 2000
Molecular characterization of Campylobacter jejuni from patients with Guillain-Barré and Miller Fisher syndromesH P Endtz, C W Ang, N van Den Braak, et al.
Scientific Reports|February 4, 2018
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linkingAnna H Turaj, Kerry L Cox, Christine A Penfold, et al.
Leukemia|August 1, 2023
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expressionJack G Fisher, Amber D P Doyle, Lara V Graham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2004
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer GroupR M Rudd, N H Gower, S G Spiro, et al.
Pageof 22